<DOC>
	<DOCNO>NCT00897520</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood patient cancer laboratory may help doctor identify biomarkers related cancer predict patient respond treatment . PURPOSE : This research study look biomarkers patient high-risk melanoma receive high-dose interferon therapy .</brief_summary>
	<brief_title>Biomarkers Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy</brief_title>
	<detailed_description>OBJECTIVES : - To screen serum specimen use high throughput protein profile platform test high number know biomarkers ( detectable antibody ) could predictors response interferon treatment , autoimmunity , disease outcome patient high-risk melanoma undergo high-dose interferon ( IFNa2b ) therapy . - To compare soluble factor across patient time point ( baseline therapy ) . - To compare pre-therapy vs post-therapy serum sample patient . - To assess kinetics soluble factor ' appearance , persistence , disappearance 12 month therapy . - To assess whether amount specific soluble factor pre-therapy sample predictive response independent therapy . - To correlate statistically significant factor S100 autoimmunity patient . - To confirm data obtain Luminex technology . OUTLINE : Patients stratify accord survival ( &lt; 2 year vs &gt; 5 year ) . Blood sample collect patient enrol E-1694 analyze use high throughput protein profile ELISA compare change level putative biomarkers interferon alfa-2b , include cytokine pair receptor , chemokines , cell adhesion molecule , metalloproteinases , angiogenic marker , growth factor , soluble receptor , signal transduction molecule , hormone , biomarkers disease dysregulated immune process , baseline therapy .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis highrisk melanoma Receiving interferon alfa2b therapy arm II clinical trial E1694 PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>stage II melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>